Další formáty:
BibTeX
LaTeX
RIS
@article{194021,
author = {Češková, Eva and Švestka, Jaromír},
article_location = {Stuttgart-New York},
article_number = {4},
keywords = {risperidone; haloperidol; double-blind; schizophrenic; schizoaffective},
language = {eng},
issn = {0176-3679},
journal = {Pharmacopsychiatry},
title = {Double-blind comparison of risperidone and haloperidol in schizophrenic and schizoaffective psychoses},
volume = {26},
year = {1993}
}
TY - JOUR
ID - 194021
AU - Češková, Eva - Švestka, Jaromír
PY - 1993
TI - Double-blind comparison of risperidone and haloperidol in schizophrenic and schizoaffective psychoses
JF - Pharmacopsychiatry
VL - 26
IS - 4
SP - 121-124
EP - 121-124
PB - Georg Thieme Verlag KG
SN - 01763679
KW - risperidone
KW - haloperidol
KW - double-blind
KW - schizophrenic
KW - schizoaffective
N2 - A double-blind eight-week study was carried out to compare the efficacy and safety of risperidone in relation to haloperidol. Sixty-two inpatients suffering from acute schizophrenic or schizoaffective psychoses diagnosed according to ICD-9 were treated with risperidone 2-20 mg daily or haloperidol 2-20 mg daily. The mean total BPRS scores were reduced from 45.5 to 32.4 in the risperidone group and from 43.1 to 28.5 in haloperidol group. There were no significant differences between the two treated groups with regard to the total BPRS score and the percentage of remissions achieved. No statistically significant difference was found between the groups in any of the factors or items except guilt feeling (p < 0.02), anxiety (p < 0.005), and factor I - anxiety/depression - (p < 0.02) in favour of haloperidol. Risperidone had the benefit of a lower incidence of extrapyramidal side-effects.
ER -
ČEŠKOVÁ, Eva a Jaromír ŠVESTKA. Double-blind comparison of risperidone and haloperidol in schizophrenic and schizoaffective psychoses. \textit{Pharmacopsychiatry}. Stuttgart-New York: Georg Thieme Verlag KG, roč.~26, č.~4, s.~121-124. ISSN~0176-3679. 1993.
|
